A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass

Anesthesia and Analgesia

Volumn 115, Issue 6, 2012, Pages 1273-1278

  Demma, Linda ^a   Levy, Jerrold H ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; FIBRINOPEPTIDE A; HEPARIN; PROTAMINE; PROTHROMBIN; RECOMBINANT THROMBOCYTE FACTOR 4; VON WILLEBRAND FACTOR;

ABNORMAL RESPIRATORY SOUND; ANTICOAGULATION; ARTICLE; ATELECTASIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CASE STUDY; CLINICAL ARTICLE; HUMAN; INFLAMMATION; LEUKOCYTE; LUNG EDEMA; PATIENT MONITORING; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE; WHEEZING;

ADULT; AGED; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CARDIOPULMONARY BYPASS; HEPARIN ANTAGONISTS; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; PLATELET COUNT; PLATELET FACTOR 4; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PROTAMINES; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84870250591     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3182662e1a     Document Type: Article

References (33)

1. Briquet-Laugier V, Lavenu-Bombled C, Schmitt A, Leboeuf M, Uzan G, Dubart-Kupperschmitt A, Rosa J P. Probing platelet factor 4 alpha-granule targeting. J Thromb Haemost 2004;2:2231-40
2. Zucker MB, Katz IR. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991;198:693-702
3. Slungaard A, Fernandez JA, Griffn JH, Key NS, Long JR, Piegors DJ, Lentz SR. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 2003;102:146-51
4. Goldberg ID, Stemerman MB, Handin RI. Vascular permeation of platelet factor 4 after endothelial injury. Science 1980;209:611-2
5. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-9
6. Petersen F, Bock L, Flad HD, Brandt E. A chondroitin sulfate proteoglycan on human neutrophils specifcally binds platelet factor 4 and is involved in cell activation. J Immunol 1998;161:4347-55
7. Maurer AM, Han ZC, Dhermy D, Briere J. Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate. J Lab Clin Med 1996;127:382-90
8. Luster AD, Greenberg SM, Leder P. The IP-10 chemokine binds to a specifc cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995;182:219-31
9. Bernabei A, Gikakis N, Maione TE, Kowalska MA, Yan Z, Niewiarowski S, Edmunds LH Jr. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;109:765-71
10. Cook JJ, Niewiarowski S, Yan Z, Schaffer L, Lu W, Stewart GJ, Mosser DM, Myers JA, Maione TE. Platelet factor 4 eff-ciently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Circulation 1992;85:1102-9
11. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998;87:781-5
12. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995;91:2188-94
13. Bernabei A, Gikakis N, Maione TE, Kowalska MA, Yan Z, Niewiarowski S, Edmunds JLH. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;109:765-71
14. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995;91:2188-94
15. Dehmer GJ, Lange RA, Tate DA, Pirwitz M, Daniel W, Fisher M, Bonnem EM. Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans. Circulation 1996;94:II347-52
16. Levy JH, Cormack JG, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 1995;81:35-7
17. Williams RD, D'Ambra MN, Maione TE, Lynch KE, Keene DF. Recombinant platelet factor 4 reversal of heparin in human cardiopulmonary bypass blood. J Thorac Cardiovasc Surg 1994;108:975-83
18. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytope-nia. Thromb Haemost 1992;68:95-6
19. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of hep-arin and platelet factor 4. Blood 1994;83:3232-9
20. Visentin G P, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specifc for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-8
21. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006;107:2346-53
22. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-9
23. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97:3300-2
24. Hill GE, Whitten CW, Landers DF. The infuence of cardio-pulmonary bypass on cytokines and cell-cell communication. J Cardiothorac Vasc Anesth 1997;11:367-75
25. Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-6
26. Bruins P, te Velthuis H, Eerenberg-Belmer AJ, Yazdanbakhsh AP, de Beaumont EM, Eijsman L, Trouwborst A, Hack CE. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost 2000;84:237-43
27. Martí nez-Sales V, Vila V, Réganon E, Goberna MA, Ferrando F, Palencia MA, Aznar J. Elevated thrombotic activity after myocardial infarction: a 2-year follow-up study. Haemostasis 1998;28:301-6
28. Banf G, Del Fabbro M. Biological variation in tests of hemosta-sis. Semin Thromb Hemost 2009;35:119-26
29. Nguyen ND, Ghaddar H, Stinson V, Chambless LE, Wu KK. ARIC hemostasis study. IV. Intraindividual variability and reliability of hemostatic factors. Thromb Haemost 1995;73:256-60
30. Mosnier LO. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fbrinolysis inhibitor (TAFI) by thrombin. J Biol Chem 2011;286:502-10
31. Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 2008;106:392-403
32. Levy JH, Zaidan JR, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. Anesth Analg 1986;65:739-42
33. Lowenstein E. Lessons from studying an infrequent event: adverse hemodynamic response associated with protamine reversal of heparin anticoagulation. J Cardiothorac Anesth 1989;3:99-107